TrialPanorama/Dataset huggingface dataset:
Please assess the completion status of the following clinical trial:

Trial Title: A Study to Evaluate Oral VT-1161 in the Treatment of Patients With Recurrent Vaginal Candidiasis (Yeast Infection)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE2
- Number of Arms: 5.0

Eligibility Criteria:
Key Inclusion Criteria:~Clinical diagnosis of symptomatic acute VVC~3 or more episodes of acute VVC in the past 12 months~Positive KOH~Minimum composite vulvovaginal signs and symptoms score of ≥3 at Screening~Composite vulvovaginal signs and symptoms score of \<3 at Baseline~Must be able to swallow tablets~Key Exclusion Criteria:~Evidence of major organ system disease~Presence or a history of another vaginal or vulvar condition(s)~History of cervical cancer~Poorly controlled diabetes mellitus~Pregnant~Recent use of topical or systemic antifungal drugs~Recent use of immunosuppressive or system corticosteroid therapies

- Gender: FEMALE
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- VT-1161 Low-dose 3-month (Type: EXPERIMENTAL): 1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
- VT-1161 Low-dose 6-month (Type: EXPERIMENTAL): 1 VT-1161 150mg tablet and 1 placebo tablet once daily for 7 days, then once weekly for 23 weeks
- VT-1161 High-dose 3-month (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 11 weeks, followed by 2 placebo tablet once weekly for 12 weeks
- VT-1161 High-dose 24-week (Type: EXPERIMENTAL): 2 VT-1161 150mg tablets once daily for 7 days, then once weekly for 23 weeks
- Placebo (Type: PLACEBO_COMPARATOR): 2 placebo tablets once daily for 7 days, then once weekly for 23 weeks

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Safety and Efficacy Study of JNS024 Extended Release (ER) in Japanese and Korean Patients With Chronic Malignant Tumor-Related Cancer Pain

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Documented clinical diagnosis of any type of cancer~* Diagnosis of chronic malignant tumor-related cancer pain with an average score for pain intensity in the past 24 hours of \>=4 on the 11-point numerical rating scale (NRS) on the day of randomization (Day -1)~* Have not received treatment with opioid analgesics within 28 days before screening (Note: codeine phosphate \[\<=60 mg/d\] or dihydrocodeine phosphate \[\<=30 mg/d\] for antitussive use are allowed)~* Dissatisfied with pain relief by the current treatment and for whom the investigator or designee judges that treatment with opioid analgesics is required~Exclusion Criteria:~* Have complicated with uncontrolled/clinically significant arrhythmia~* Have previous or concurrent presence of any disease which may develop increased intracranial pressure, disturbance of consciousness, lethargy, or respiratory problems such as traumatic encephalopathy with cerebral contusion, intracranial hematoma, disturbance of consciousness, brain tumor, cerebral infarction, transient ischemic attack, epilepsy or convulsive diseases~* Have history of alcohol and/or drug abuse~* Have any disease for which opioids are contraindicated such as serious respiratory depression of serious chronic obstructive pulmonary disease, bronchial asthma attack, cardiac failure secondary to chronic pulmonary disease, paralytic ileus, status epileptics, tetanus, strychnine poisoning, acute alcohol poisoning, hypersensitivity to opium alkaloid, hemorrhagic colitis, or bacterial diarrhea

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: 99 Years
- Healthy Volunteers: f

Study Arms:
- 001 (Type: EXPERIMENTAL): R331333 (referred to as JNS024 ER or CG5503) One 25 mg to 200 mg capsule twice daily for 4 weeks.
- 002 (Type: ACTIVE_COMPARATOR): Oxycodone CR One 5 mg to 40 mg capsule twice daily for 4 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Study of Efficacy and Safety of Twice Daily Oral Iptacopan (LNP023) in Adult PNH Patients Who Are Naive to Complement Inhibitor Therapy

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male and female participants ≥ 18 years of age with a diagnosis of PNH confirmed by high-sensitivity flow cytometry with RBCs and WBCs clone size ≥ 10%~* Mean hemoglobin level \<10 g/dL~* LDH \> 1.5 x Upper Limit of Normal (ULN)~* Vaccination against Neisseria meningitidis infection is required prior to the start of study treatment~* If not received previously, vaccination against Streptococcus pneumoniae and Haemophilus influenzae infections should be given~Exclusion Criteria:~* Prior treatment with a complement inhibitor, including anti-C5 antibody~* Known or suspected hereditary complement deficiency~* History of hematopoietic stem cell transplantation~* Patients with laboratory evidence of bone marrow failure (reticulocytes \<100x109/L; platelets \<30x109/L; neutrophils \<0.5x109/L).~* Active systemic bacterial, viral (incl. COVID-19)or fungal infection within 14 days prior to study drug administration.~* History of recurrent invasive infections caused by encapsulated organisms, e.g. meningococcus or pneumococcus.~* Major concurrent comorbidities including but not limited to severe kidney disease (e.g., dialysis), advanced cardiac disease (e.g., NYHA class IV heart failure), severe pulmonary disease (e.g., severe pulmonary hypertension (WHO class IV)), or hepatic disease (e.g., active hepatitis) that in the opinion of the investigator precludes participant's participation in the study.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- LNP023 (Type: EXPERIMENTAL): Participants receive LNP023 at a dose of 200 mg orally b.i.d

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Topical Composition Therapy (2013-MCN-333) for the Treatment of Melasma

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE2
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Informed subject consent will be obtained from those patients meeting the following inclusion criteria:~* Male and female patients 18 to 65 years age~* Moderate to severe melasma, as measured by the Melasma Area Severity Index score greater than or equal to 16~* No prior use of topical skin-lightening agents for 1 month prior to study entry~* Good general health as confirmed by medical history~* Female patients of child-bearing potential with a negative urine pregnancy test who agree to use effective methods of birth control or remain abstinent during treatment. Participants must use birth control for the entire study and for at least 1 week after the last application of the study formulation. Acceptable methods of birth control include ongoing hormonal contraception methods, (such as birth control pills, patches, injections, vaginal ring, or implants), barrier methods (such as a condom or diaphragm used with a spermicide), intrauterine devices, tubal ligation, or abstinence~* Patients who are willing and capable of cooperating to the extent and degree required by the protocol; and~* Patients who read and sign an approved informed consent for this study~Exclusion Criteria:~* Vulnerable study population~* Exposure to topical skin-lightening agents within 1 month of study entry, including:~  1. Topical corticosteroids~ 2. Topical bleaching products~ 3. Topical retinoids~* Use of systemic preparations within 1 month of study entry, including:~  1. Systemic corticosteroids~ 2. Systemic cyclosporine, interferon~ 3. Systemic acitretin, etretinate, isotretinoin~ 4. Systemic methotrexate~ 5. Systemic photoallergic, phototoxic and/or photosensitizing drugs~* UV light therapy and sunbathing~* Inability to communicate or cooperate with the Principal Investigator and/or Investigators due to language problems, poor mental development or impaired cerebral function~* Pregnant or nursing women~* Women planning a pregnancy within the study period

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 65 Years
- Healthy Volunteers: f

Study Arms:
- Illuminate Cream (Type: EXPERIMENTAL): Illuminate Cream is a skin-lightening formulation containing multiple drugs, including a retinoid, calcineurin inhibitor, anti-tyrosinase agent and sunscreen microfine zinc oxide. Approximately 0.5 grams to be applied topically to affected areas of skin once per day for 20 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Seasonal Malaria Vaccination (RTS,S/AS01) and Seasonal Malaria Chemoprevention (SP/AQ)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: TRIPLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* The child is a permanent resident of the study area and likely to remain a resident for the duration of the trial~* The child is 5 - 17 months of age at the time of first vaccination~* A parent or legally recognised guardian provides informed consent for the child to join the trial~Exclusion Criteria:~* The child is a transient resident in the study area~* The child is in care~* The age of the child is outside the stipulated range~* The child has a history of an adverse reaction to SP or AQ~* The child has a serious underlying illness, including known HIV infection, unless this is well controlled by treatment, or severe malnutrition (weight for age or mid arm circumference Z scores \< 3 SD)~* The child is known to have an immune deficiency disease or is receiving an immunosuppressive drug~* The child has previously received a malaria vaccine.~* The child is enrolled in another malaria intervention trial~* The parents or guardians do not provide informed consent

- Gender: ALL
- Minimum Age: 5 Months
- Maximum Age: 17 Months
- Healthy Volunteers: f

Study Arms:
- SMC with SP+AQ (Type: ACTIVE_COMPARATOR): Administration of RABIPUR® in Year 1 and Hepatitis A vaccine in Year 2 and 3, followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.
- RTS,S/AS01 (Type: ACTIVE_COMPARATOR): Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with placebo in Year 1,2 and 3.
- RTS,S/AS01 PLUS SMC with SP+AQ (Type: ACTIVE_COMPARATOR): Administration of the malaria vaccine RTS,S/AS01 followed by 4 cycles of SMC with sulphadoxine/pyrimethamine plus amodiaquine in Year 1,2 and 3.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: A Trial of PTS Via Intratumoral Injection in Patients With Central Air Way NSCLC Severe Obstruction

Study Design Characteristics:
- Allocation: None
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Male or female inpatients, aged 18 to 83 years old.~* Patients with central air way non-small cell lung cancer (NSCLC) severe obstruction; definition of severe airway obstruction: ≥1/2 trachea is obstructed by tumor; and/or block ≥2/3 of primary bronchi, right and middle bronchi. And the longest diameter of the lesion \> 0.5 cm.~* Pathologically confirmed lung cancer.~* Patients with tracheal tumor lesions suitable for local intratumoral injection via fibro-bronchoscopy.~* At least one measurable lesion that could be evaluated by imaging examination (bronchoscopy, CT, MRI or X-ray etc.) according to the Response Evaluation Criteria in Solid Tumors.~* Blood platelet count ≥ 100,000/mm3.~* Subjects who were able to understand and comply with the trial protocol and give written consent.~Exclusion Criteria:~* Brain metastases.~* History of cardiovascular diseases, including congestive heart failure \> New York Heart Association (NYHA) Grade II. Patients with unstable angina pectoris (angina pectoris symptoms at rest), recent angina pectoris (occurred in the recent 3 months) or with myocardial infarction in recent 6 months must be excluded.~* Severe infections or dysbolism.~* Poor hepatic functional reserve or severe hepatocirrhosis, with abnormal blood coagulation indicators.~* Poor general conditions or cachexia.~* The target lesion had been treated with radiotherapy within 6 months.~* Pregnant or breast-feeding woman.~* Known hypersensitivity to PTS or related compounds.~* Lung cancer lesions not suitable for local treatment.~* Any other reason deemed reasonable by the investigator.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 83 Years
- Healthy Volunteers: f

Study Arms:
- Para-Toluenesulfonamide (Type: EXPERIMENTAL): 1. .The dose of PTS injected into multiple points in a single tumor was about 0.1-1.0 mL, and the appropriate specific doses were kept within the tumor without leakage. An appropriate low dose could be given firstly, and the following doses could be adjusted based on the response of patient and the tumor.~2. . In general, the daily dose of PTS injected into a single tumor was no more than 5mL, and the daily dose of PTS was no more than 10mL for each patient.~The injection was provided 2-3 times a week, with 2 weeks as a cycle of treatment. No less than 4 times of PTS treatment were recomended for the first cycle of treatment, and for other cycles of treatment, the number of PTS injections could be adjusted appropriately based on the condition of the patient.

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: The Impact of Total Body Skin Examination on Skin Cancer Detection

Study Design Characteristics:
- Allocation: NON_RANDOMIZED
- Intervention Model: SINGLE_GROUP
- Observational Model: None
- Primary Purpose: DIAGNOSTIC
- Time Perspective: None
- Masking: NONE
- Phase: None
- Number of Arms: 1.0

Eligibility Criteria:
Inclusion Criteria:~* Consecutive, unselected adult (18 years or more) patients with any skin disorders. Skin disorder must be localized on a limited body area and should NOT require total body skin examination (TBSE) to be diagnosed and/or treated.~Exclusion Criteria:~* Patients who ask for or need TBSE as the main reason for consultation. A patient must be also excluded if a significant part of the body should be undressed for diagnosis and/or treatment (i.e. if the shirt or trousers should be removed for diagnosis and/or treatment, then the patient must be excluded).~* patients under the age of 18 years.~* patients who do not agree to get TBSE.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 95 Years
- Healthy Volunteers: t

Study Arms:
- Skin cancer screening (Type: OTHER): None

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: An Efficacy Study of Stain Control of a 67% Sodium Bicarbonate Containing Toothpaste on Chlorhexidine Tooth Staining

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: PREVENTION
- Time Perspective: None
- Masking: SINGLE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* Good oral health in the opinion of the investigator (excluding gingivitis)~* A minimum of 11 of the 12 permanent gradable anterior teeth at screening~* Stain levels on the buccal surfaces of the 6 maxillary and 6 mandibular anterior teeth need to be at least mild and present on a minimum of 4 teeth~* Modification of the Lobene Stain Index - At Visit 2, a baseline total MLSI Intensity x Area score (four sites per tooth) of greater than or equal to 8 for facial surfaces of anterior teeth.~Exclusion Criteria:~* Pregnant women or women who are intending to become pregnant over the duration of the study~* Known or suspected intolerance or hypersensitivity to Chlorhexidine or other study materials (or closely related compounds).~* Current use of Chlorhexidine, Cetylpyridinium Chloride or any marketed mouthwash~* Past or current use of any drug which is known to be associated with tooth discolouration within 30 days of screening or during the study period.~* Recent history (within the last 1 year) of alcohol or other substance abuse~* Dental conditions / disease requiring immediate treatment; Crowns or veneers on more than one anterior tooth; pre-existing sensitivity to oral care products; severe periodontitis; severe recession; dental implants; active carious lesions on anterior teeth; oral lesions/manifestations; prone to aphthous stomatitis and ulceration etc.~* Participant with untreated oral mucosal disease which in the opinion of the investigator could interfere with the study.~* Medical condition which would require the use of prophylactic antibiotics prior to dental cleanings~* Current or relevant history of any serious, severe or unstable physical or psychiatric illness or any medical disorder that would make the participant unlikely to fully complete the study or any condition that presents undue risk from the study treatment or procedures in the opinion of the investigator or dental assessor.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 64 Years
- Healthy Volunteers: t

Study Arms:
- Sodium bicarbonate/ Sodium Fluoride toothpaste (Type: OTHER): Marketed Sodium bicarbonate toothpaste containing 1400 parts per million (ppm) fluoride as Sodium fluoride (NaF)
- Sodium fluoride toothpaste (Type: ACTIVE_COMPARATOR): Non-sodium bicarbonate toothpaste containing 1450ppm fluoride as NaF
- Chlorhexidine digluconate mouthwash (Type: OTHER): 0.2% w/v Chlorhexidine digluconate mouthwash for rinsing post-brushing with study toothpastes

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete
Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Oral LPCN 1021 in Men With Low Testosterone or Hypogonadism

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~1. Documented diagnosis of primary hypogonadism (congenital or acquired) or hypogonadotropic hypogonadism (congenital or acquired).~2. Serum total testosterone \< 300 ng/dL based on 2 consecutive blood samples~Exclusion Criteria:~A subject will not be eligible for study participation if he meets any of the following criteria.~1. History of significant sensitivity or allergy to androgens, castor oil or product excipients.~2. Clinically significant findings in the prestudy examinations.~3. Abnormal prostate digital rectal examination (DRE) with palpable nodule(s) or I-PSS score \> 19 points.~4. Body mass index (BMI) ≥ 38 kg/m2.~5. Clinically significant abnormal laboratory values~6. Positive test result for hepatitis A virus immunoglobulin M (HAV-IgM), hepatitis B surface antigen (HBsAg) or hepatitis C virus antibody (HCV Ab) or human immunodeficiency virus antibodies (HIV Ab).~7. History of seizures or convulsions, including febrile, alcohol or drug withdrawal seizures.~8. History of gastric surgery, cholecystectomy, vagotomy, bowel resection or any surgical procedure that might interfere with gastrointestinal motility, pH or absorption.~9. History of any clinically significant illness, infection, or surgical procedure within 1 month prior to study drug administration.~10. History of stroke or myocardial infarction within the past 5 years.~11. History of, or current or suspected, prostate or breast cancer.~12. History of diagnosed, severe, untreated, obstructive sleep apnea.~13. History of abuse of alcohol or any drug substance in the opinion of the investigator within the previous 2 years.~14. History of long QT syndrome or unexplained sudden death in a first degree relative (parent, sibling, or child).~15. Concurrent treatment with medications which may impact the absorption, distribution, metabolism or excretion of testosterone undecanoate (TU) or place the subject at risk for treatment with testosterone.~16. Subject has a partner who is currently pregnant or planning pregnancy during the course of the clinical trial.

- Gender: MALE
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Oral testosterone undecanoate, LPCN 1021 (Type: EXPERIMENTAL): Oral testosterone undecanoate: Initial dose: 225 mg TU BID. Dose titrated up to 300 mg TU BID or down to 150 mg TU BID based on serum T at Week 3 and 7.
- Topical testosterone gel 1.62 % (Type: OTHER): Topical testosterone gel 1.62%: Initial dose: 40.5 mg T once daily. Dose titrated down to 20.25 mg or up to 81 mg based on serum T on Days 14 and 28

Based on this trial design, predict the completion outcome and termination type (if applicable).

Answer: outcome: complete